- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Glucotrack, Inc.: Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor | 1 | GlobeNewswire (USA) | ||
| Mo | Glucotrack, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| Mo | GlucoTrack, Inc.: Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights | 19 | GlobeNewswire (Europe) | Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption... ► Artikel lesen | |
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| Mo | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.03. | GCTK-Aktie stürzt | 3 | Investing.com Deutsch | ||
| 13.03. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.02. | Glucotrack, Inc.: Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member | 1 | GlobeNewswire (USA) | ||
| 26.02. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.02. | Glucotrack's 3-year diabetes sensor implant clears initial human safety trial | 1 | FierceBiotech | ||
| 05.02. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.02. | GlucoTrack Drops 24% Despite Successful First-in-Human Study Of CGM | - | RTTNews | ||
| 04.02. | Glucotrack announces pricing of $3M public offering | 2 | Seeking Alpha | ||
| 04.02. | Glucotrack sets terms for $3 million public stock offering | 1 | Investing.com | ||
| 04.02. | Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering | 4 | GlobeNewswire (USA) | ||
| 04.02. | Glucotrack soars on completion of first human clinical study of continuous blood glucose monitor | 2 | Seeking Alpha | ||
| 04.02. | Glucotrack completes first-in-human continuous blood glucose monitor implant study | 3 | MassDevice | ||
| 04.02. | Glucotrack reports success in first human glucose monitor trial | 5 | Investing.com | ||
| 04.02. | Glucotrack, Inc.: Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor | 201 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization... ► Artikel lesen | |
| 30.01. | Glucotrack to execute 1-for-20 reverse stock split | 4 | Seeking Alpha | ||
| 30.01. | Glucotrack announces 1-for-20 reverse stock split | 2 | Investing.com |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 48,400 | -7,90 % | HAUCK AUFHÄUSER INVESTMENT BANKING stuft ECKERT & ZIEGLER auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Hauck Aufhäuser Investment Banking hat die Einstufung für Eckert & Ziegler auf "Buy" mit einem Kursziel von 66 Euro belassen. Als Lieferant radioaktiver Komponenten profitiere... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,104 | -2,79 % | Sernova Biotherapeutics Inc: Sernova to continue to Cohort C T1D trial in H2 2025 | ||
| SYNLAB | 12,880 | +11,03 % | Eurofins Scientific: Eurofins Announces the Successful Closing of Its Acquisition of SYNLAB's Clinical Diagnostics Operations in Spain | Regulatory News:
Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing, with a rapidly developing presence in highly specialised and molecular clinical diagnostics... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,031 | -2,53 % | Turnaround Spekulation! Das könnte der 13.000% PODD-Moment sein! | ||
| ATOSSA THERAPEUTICS | 0,556 | +0,18 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications | SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
| UNIDOC HEALTH | 0,206 | -0,96 % | UniDoc Health Corp.: UniDoc Announces LIFE Offering | THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / April 4, 2025 / UniDoc Health Corp. (CSE:UDOC) ("UniDoc"... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,792 | -1,32 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports First Full-Year Profit in 2024 | Synergies Between Health Care and Insurance Drive Scalable GrowthAI Innovations Fuel Continued Success
SHANGHAI and HONG KONG, March 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,520 | -100,00 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,022 | +23,33 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,284 | -1,39 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 0,886 | -1,77 % | Cytosorbents Corp: CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 2024 marked by strong commercial execution and improved operating leverage
Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and... ► Artikel lesen | |
| QUIDELORTHO | 26,600 | +3,10 % | QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results | SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care... ► Artikel lesen | |
| VERU | 0,519 | +0,48 % | Veru Aktie: Kreuzung ohne klare Richtung! | Die Veru-Aktie konnte im jüngsten Handel einen leichten Aufschwung verzeichnen. Am 22. März stieg der Kurs um 2,35% auf 0,48 EUR, was eine positive Entwicklung gegenüber dem Vortagsschluss darstellt.... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,588 | +4,53 % | Tempest Therapeutics: Tempest Reports Year End 2024 Financial Results and Provides Business Update | • Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement... ► Artikel lesen |
Das Unternehmen GLUCOTRACK INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -10,02 % bei einem Aktienkurs von 0,168 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.
